Glazer Capital, LLC Exits Position in Amicus Therapeutics, Inc. (FOLD)

On May 1, 2026, Glazer Capital, LLC and Paul J. Glazer filed a Schedule 13G regarding their holdings in Amicus Therapeutics, Inc. (FOLD). The filing indicates that as of the event date on April 24, 2026, the reporting persons have ceased to be the beneficial owners of more than five percent of the company's common stock. Specifically, the reporting persons now report owning 0 shares, representing a 0.0% ownership stake in the issuer. Previously, the reporting persons may have been deemed to beneficially own more than 5% of the outstanding shares, but they have now fully exited this significant position. Glazer Capital, LLC, a Delaware limited liability company, served as the investment manager for various funds and managed accounts, with Paul J. Glazer acting as the Managing Member. The filing was made under Rule 13d-1(c), certifying that the securities were not held for the purpose of influencing or changing the control of the issuer. The principal business office for the reporting persons is located in New York, New York.